Spectrum Pharmaceuticals SPPI shares are trading higher on Thursday after JMP Securities initiated coverage on the stock with an Outperform rating and announced a price target of $12 per share.
Spectrum Pharmaceuticals operates in the health care sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
Spectrum Pharmaceuticals shares were up 7.78% at $4.50 at the time of publication on Thursday. The stock has a 52-week high of $10.57 and a 52-week low of $1.74.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
